All Stories

  1. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
  2. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
  3. First Human Case of Tick-Borne Encephalitis in Non-Endemic Region in Italy: A Case Report
  4. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
  5. Semi-Quantitative Ultrasonographic Evaluation of NAFLD
  6. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review
  7. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
  8. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
  9. Extra-Hepatic Manifestations and Complications of Nonalcoholic Fatty Liver Disease
  10. A critical appraisal of the use of ultrasound in hepatic steatosis
  11. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
  12. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
  13. Clinical relevance of liver histopathology and different histological classifications of NASH in adults
  14. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases
  15. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
  16. NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
  17. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?
  18. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis
  19. Alcohol and Steatosis: The Japanese Paradox
  20. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
  21. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.
  22. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight
  23. A “systems medicine” approach to the study of non-alcoholic fatty liver disease
  24. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
  25. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
  26. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV
  27. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
  28. Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma
  29. Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?
  30. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
  31. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications
  32. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study
  33. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease
  34. Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings
  35. Inflammatory hepatocellular adenomatosis, metabolic syndrome, polycystic ovary syndrome and non-alcoholic steatohepatitis: Chance tetrad or association by necessity?
  36. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology
  37. Nonalcoholic fatty liver disease and aging: Epidemiology to management
  38. Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen
  39. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
  40. Relationship of Serum Fetuin-A Levels with Coronary Atherosclerotic Burden and NAFLD in Patients Undergoing Elective Coronary Angiography
  41. Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis
  42. Magnetic Resonance for Quantitative Assessment of Liver Steatosis: A New Potential Tool to Monitor Antiretroviral-Drug-Related Toxicities
  43. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD
  44. Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease
  45. Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?
  46. Nonalcoholic fatty liver disease activity score and Brunt's pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?
  47. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?
  48. Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity
  49. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease
  50. Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors
  51. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes
  52. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?
  53. The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology
  54. Is Cholangiocarcinoma Another Complication of Insulin Resistance: A Report of Three Cases